BR112022021520A2 - Composição de liberação atrasada para administração peroral - Google Patents
Composição de liberação atrasada para administração peroralInfo
- Publication number
- BR112022021520A2 BR112022021520A2 BR112022021520A BR112022021520A BR112022021520A2 BR 112022021520 A2 BR112022021520 A2 BR 112022021520A2 BR 112022021520 A BR112022021520 A BR 112022021520A BR 112022021520 A BR112022021520 A BR 112022021520A BR 112022021520 A2 BR112022021520 A2 BR 112022021520A2
- Authority
- BR
- Brazil
- Prior art keywords
- delayed release
- salt
- peroral administration
- release composition
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006074.5A GB202006074D0 (en) | 2020-04-24 | 2020-04-24 | New composition |
| PCT/GB2021/050993 WO2021214487A1 (en) | 2020-04-24 | 2021-04-23 | New delayed release composition for peroral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021520A2 true BR112022021520A2 (pt) | 2023-01-24 |
Family
ID=71080159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021520A BR112022021520A2 (pt) | 2020-04-24 | 2021-04-23 | Composição de liberação atrasada para administração peroral |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US11654115B2 (https=) |
| EP (2) | EP4218737A1 (https=) |
| JP (3) | JP7418587B2 (https=) |
| KR (1) | KR20230005239A (https=) |
| CN (1) | CN115811971A (https=) |
| AU (1) | AU2021258542B2 (https=) |
| BR (1) | BR112022021520A2 (https=) |
| CA (1) | CA3180850A1 (https=) |
| DK (1) | DK4138789T3 (https=) |
| ES (1) | ES2955915T3 (https=) |
| FI (1) | FI4138789T3 (https=) |
| GB (1) | GB202006074D0 (https=) |
| HR (1) | HRP20231012T1 (https=) |
| HU (1) | HUE062897T2 (https=) |
| IL (1) | IL297374B1 (https=) |
| LT (1) | LT4138789T (https=) |
| MA (1) | MA59397B1 (https=) |
| MD (1) | MD4138789T2 (https=) |
| MX (1) | MX2022013069A (https=) |
| PL (1) | PL4138789T3 (https=) |
| PT (1) | PT4138789T (https=) |
| RS (1) | RS64568B1 (https=) |
| SI (1) | SI4138789T1 (https=) |
| SM (1) | SMT202300289T1 (https=) |
| WO (1) | WO2021214487A1 (https=) |
| ZA (1) | ZA202211461B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004094D0 (en) * | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202201723D0 (en) * | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
| WO2023152503A1 (en) * | 2022-02-10 | 2023-08-17 | Vicore Pharma Ab | Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59139317A (ja) * | 1983-01-31 | 1984-08-10 | Teisan Seiyaku Kk | 持続性のニフエジピン製剤 |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| JP2003325642A (ja) | 2002-05-09 | 2003-11-18 | Sansho Pharmaceutical Co Ltd | 腸溶性皮膜付き硬質空カプセルと、腸溶性皮膜付き硬質空カプセルの製造方法と、腸溶性皮膜付き硬質カプセル剤 |
| US20050143435A1 (en) * | 2003-10-10 | 2005-06-30 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker |
| JP2008502699A (ja) | 2004-06-14 | 2008-01-31 | セプラコール・インコーポレイテッド | 肺疾患治療方法、及びそのための組成物 |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| ES2793530T3 (es) | 2014-05-19 | 2020-11-16 | Tillotts Pharma Ag | Cápsulas revestidas de liberación modificada |
| EP2946773A1 (en) | 2014-05-19 | 2015-11-25 | Tillotts Pharma AG | Modified release coated capsules |
| CN107405406A (zh) | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| JPWO2017022248A1 (ja) | 2015-08-04 | 2018-05-24 | 富士カプセル株式会社 | 腸溶性カプセル |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| WO2019183513A1 (en) * | 2018-03-22 | 2019-09-26 | University Of Iowa Research Foundation | Compositions and methods for the treatment and prevention of muscular dystrophy |
| JP7044360B2 (ja) | 2018-04-02 | 2022-03-30 | 三生医薬株式会社 | ハードカプセル用コーティング剤及びそれを用いたハードカプセル剤の製造方法 |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
-
2020
- 2020-04-24 GB GBGB2006074.5A patent/GB202006074D0/en not_active Ceased
-
2021
- 2021-04-23 EP EP23177726.9A patent/EP4218737A1/en active Pending
- 2021-04-23 RS RS20230717A patent/RS64568B1/sr unknown
- 2021-04-23 HU HUE21724011A patent/HUE062897T2/hu unknown
- 2021-04-23 KR KR1020227040358A patent/KR20230005239A/ko active Pending
- 2021-04-23 JP JP2022540547A patent/JP7418587B2/ja active Active
- 2021-04-23 PL PL21724011.8T patent/PL4138789T3/pl unknown
- 2021-04-23 AU AU2021258542A patent/AU2021258542B2/en active Active
- 2021-04-23 WO PCT/GB2021/050993 patent/WO2021214487A1/en not_active Ceased
- 2021-04-23 SM SM20230289T patent/SMT202300289T1/it unknown
- 2021-04-23 BR BR112022021520A patent/BR112022021520A2/pt unknown
- 2021-04-23 DK DK21724011.8T patent/DK4138789T3/da active
- 2021-04-23 LT LTEPPCT/GB2021/050993T patent/LT4138789T/lt unknown
- 2021-04-23 FI FIEP21724011.8T patent/FI4138789T3/fi active
- 2021-04-23 MX MX2022013069A patent/MX2022013069A/es unknown
- 2021-04-23 MD MDE20230229T patent/MD4138789T2/ro unknown
- 2021-04-23 CN CN202180042664.2A patent/CN115811971A/zh active Pending
- 2021-04-23 IL IL297374A patent/IL297374B1/en unknown
- 2021-04-23 HR HRP20231012TT patent/HRP20231012T1/hr unknown
- 2021-04-23 PT PT217240118T patent/PT4138789T/pt unknown
- 2021-04-23 EP EP21724011.8A patent/EP4138789B1/en active Active
- 2021-04-23 CA CA3180850A patent/CA3180850A1/en active Pending
- 2021-04-23 ES ES21724011T patent/ES2955915T3/es active Active
- 2021-04-23 MA MA59397A patent/MA59397B1/fr unknown
- 2021-04-23 SI SI202130057T patent/SI4138789T1/sl unknown
-
2022
- 2022-03-17 US US17/696,997 patent/US11654115B2/en active Active
- 2022-10-19 ZA ZA2022/11461A patent/ZA202211461B/en unknown
-
2023
- 2023-04-14 US US18/300,739 patent/US12121614B2/en active Active
- 2023-09-29 JP JP2023169472A patent/JP7663647B2/ja active Active
-
2024
- 2024-09-17 US US18/887,301 patent/US20250235408A1/en active Pending
-
2025
- 2025-04-04 JP JP2025062545A patent/JP2025106410A/ja active Pending
- 2025-09-17 US US19/331,702 patent/US20260007608A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022021520A2 (pt) | Composição de liberação atrasada para administração peroral | |
| AU2020256326B2 (en) | Novel Anti-Infective Strategy Against Influenza Virus And S.aureus Coinfections | |
| Liao et al. | Germacrone inhibits early stages of influenza virus infection | |
| EP4615506A1 (en) | Use of gsk-3 activatior to modulate proteasome activity to prevent ageing associated conditions and diseases | |
| BR112017027798A2 (pt) | compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| AbouAitah et al. | Virucidal action against avian influenza H5N1 virus and immunomodulatory effects of nanoformulations consisting of mesoporous silica nanoparticles loaded with natural prodrugs | |
| BR112018002304A8 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
| BR112022021511A2 (pt) | Composição de pó seco para administração peroral | |
| Smee et al. | Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice | |
| EA201700182A1 (ru) | Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой | |
| BR112015020443A2 (pt) | desamorfização de formulações secadas por atomização via mistura por atomização | |
| PL217628B1 (pl) | Zastosowanie resweratrolu do wytwarzania leku wywierającego działanie inhibitorowe na replikację wirusa grypy do zapobiegania i/lub leczenia infekcji wywołanej wirusem grypy | |
| BR112022022081A2 (pt) | Composição farmacêutica inalável, método para tratar uma infecção viral pulmonar, pó seco inalável, composição farmacêutica, sistema de inalação para o uso no tratamento ou profilaxia de uma infecção viral pulmonar | |
| EA026665B1 (ru) | Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением | |
| WO2021211098A1 (en) | Prevention and treatment of viral infection-induced organ failure | |
| Kandimalla et al. | Exosome-mediated antiviral testing system and identification of Punicalagins and Anthocyanidins as promising antiviral agents against SARS-CoV-2 | |
| EP4376864A1 (en) | Therapeutic formulations from pelargonium sp. and method of use in respiratory viral infections | |
| JP2004262924A (ja) | インフルエンザウイルス感染予防剤 | |
| Zubenko et al. | Study on antiviral activity of coordination compound based on molecular iodine against influenza a virus | |
| WO2017177919A1 (zh) | 一种能够抑制流感病毒pb2蛋白与rna帽结合的化合物 | |
| BR112018072669A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratamento uma doença ou condição que se beneficiaria da inibição de ido1, e, uso de um composto ou sal | |
| CN105920004B (zh) | 1，2，4-三取代哌嗪化合物在制备抗流感病毒药物中的用途 | |
| BR112018001716A2 (pt) | composto de derivado de 1,3,4-oxadiazol amida como inibidor de histona desacetilase 6 e composição farmacêutica contendo o mesmo | |
| RU2687551C3 (ru) | Стабильная фармацевтическая композиция с фиксированной дозой, содержащая мометазон и олопатадин |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |